Dr. Kriachok: attending SOHO 2024 was a ‘great honor’
Iryna Kriachok, MD, PhD, of the National Cancer Institute in Kyiv, Ukraine, explains in both Ukrainian and English why being invited to the
Lymphoma
The Twelfth Annual Meeting of the Society of Hematologic Oncology
Video Interviews
Society Updates
66th American Society of Hematology Annual Meeting & Exposition
Myeloma
Daratumumab monotherapy superior to active monitoring in high-risk smoldering myeloma
Daratumumab demonstrated a clinically meaningful and significant benefit compared with active monitoring, the current standard of care, for patients with high-risk smoldering multiple
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Lymphoma
News
Video Interviews
Dr. Lu discusses CD7-targeted CAR-T cell therapy at ASH 2024
Peihua Lu, MD, of Beijing Lu Daopei Institute of Hematology in China, stopped by the SOHO booth to speak with SOHO Insider during
Multiple Myeloma
News
Introducing SOHO Insider
SOHO Insider EIC Sagar Lonial, MD, announces the new digital and print newsroom SOHO Insider from the Society of Hematologic Oncology (SOHO).
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
Fixed-duration regimens outperform SOC in treatment-naïve CLL
Fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab improved progression-free survival over fludarabine-cyclophosphamide-rituximab or bendamustine-rituximab in treatment-naïve chronic lymphocytic leukemia (TN CLL), according
66th American Society of Hematology Annual Meeting & Exposition
Leukemia
Asciminib benefit-risk profile bests other TKIs in CML
Results from the phase 3 ASC4FIRST study presented at the 2024 American Society of Hematology Annual Meeting & Exposition showed that asciminib had
Meetings / Conferences
66th American Society of Hematology Annual Meeting & Exposition
Lymphoma
Tafasitamab plus lenalidomide, rituximab improves PFS in patients with relapsed or refractory follicular lymphoma
Addition of tafasitamab, a humanized CD19-targeting monoclonal antibody (mAb), to lenalidomide plus rituximab resulted in significant and clinically meaningful improvement in progression-free survival (PFS),
Meetings / Conferences
MDS
Smoking associated with MDS mutations, progression
Results from a prospective study presented at the American Society of Hematology Annual Meeting & Exposition showed that tobacco smoking was associated with
Society Updates
Save the date for SOHO 2025 in Houston, Texas
The Society of Hematologic Oncology (SOHO) has announced that its 2025 meeting will be held between Wednesday, September 3, 2025, and Saturday, September
Cellular Therapy
T-Cell Lymphoma
CTX130 demonstrates potential in relapsed or refractory T-cell lymphoma
The chimeric antigen receptor (CAR)-T cell therapy CTX130 (volamcabtagene durzigedleucel) showed encouraging results in patients with heavily pretreated relapsed or refractory T-cell lymphoma,